Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Gartner Inc (IT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Gartner Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while Gartner Inc trades at $134 (market cap $8.92B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.5× Gartner Inc's market cap. Which is the better fit depends on your goals.
| ALNY | IT | |
|---|---|---|
Market Cap | $39.89B | $8.92B |
Sector | Health | Technology |
52-Week High | $491.22 | $374.40 |
52-Week Low | $278.09 | $125.68 |
Enterprise Value | $38.15B | $10.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Gartner (IT) trades at $133.24, up 0.41% today, with a bearish technical signal but strong recent earnings beats. The company shows robust profitability with a 68.99% gross margin and 11.44% net margin, though 2025 net income declined to $729M from $1.3B in 2024. Analyst consensus is mixed with a $157.60 price target, while news highlights ongoing investigations and industry events.
Outlook is cautious due to technical bearishness and net cash outflows, but valuation appears reasonable with a P/E of 13.17. Risks include competitive pressures and the recent legal investigation. Upside potential exists if earnings momentum continues and sentiment improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
